Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment (Q33442358)

26 July 2017

title

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment (English)

1 reference

Juan Eduardo Megías-Vericat

26 July 2017

1 reference

acute myeloid leukemia

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Miguel A Sanz

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Pau Montesinos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

María José Herrero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Federico Moscardó

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Virginia Bosó

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

David Martínez-Cuadrón

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Luis Rojas

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Rebeca Rodríguez-Veiga

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Blanca Boluda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Luis Sendra

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

José Cervera

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

José Luis Poveda

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

Salvador F Aliño

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

publication date

2 June 2017

1 reference

26 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

volume

58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

2880-2894

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

Pharmacogenomics and the treatment of acute myeloid leukemia.

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Potential mechanisms of resistance to cytarabine in AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Effect of genetic alterations of cytarabine-metabolizing enzymes in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

The 5'-nucleotidases as regulators of nucleotide and drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428194.2017.1323267

10.1080/10428194.2017.1323267

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28573946 AND SRC:MED&resulttype=core&format=json

12 June 2020

1 reference